Our focus
Major Depression affects at least one in ten people worldwide, inflicting not only devastating individual suffering but also standing as the leading cause of suicides. Depression causes extensive economic damage stemming from treatment costs, work disability, and early retirement.
These facts have prompted INNOVADE Therapeutics to address this challenge by developing groundbreaking solutions for the innovation crisis in the treatment of depression.
Backed by a robust and successful academic background and many collaborations worldwide, our team of scientists and researchers has identified novel classes of antidepressants through fundamental neuroscience research. These medications work by enhancing plasticity and restructuring synapses and networks within the human brain. Our primary small molecule candidate targets a subunit of specific receptors on inhibitory nerve cells in the brain, resulting in a rapidly effective antidepressant with fewer side effects.
Demonstrates efficacy and the mechanism of action in animal models
Ensures compound safety through comprehensive toxicology and pharmacological studies
Develops optimal drug delivery systems and establishes manufacturing processes
Advances therapeutic candidates through clinical trials to validate safety and efficacy in humans
